{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NUZ.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.12,"timestamp":1744870320000,"preClose":0.1,"halted":0,"volume":213792,"delay":0,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":492305766,"eps":-0.033278,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"04-17 16:12:00 AEST","open":0.105,"high":0.12,"low":0.105,"amount":24366,"amplitude":0.15,"askPrice":0.12,"askSize":26273,"bidPrice":0.11,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.033278,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.1,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":1.458994444797578,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-60.46%","roe":"-150.50%","lyrEps":-0.020692,"volumeRatio":1.458994444797578,"shares":492305766,"dividePrice":0,"high":0.12,"amplitude":0.15,"preClose":0.1,"low":0.105,"week52Low":0.096,"pbRate":"4.96","psRate":"38.97","week52High":0.31,"institutionHeld":0,"latestPrice":0.12,"committee":-0.448626,"eps":-0.033278,"divideRate":0,"volume":213792,"delay":0,"ttmEps":-0.033278,"open":0.105,"prevYearClose":0.17,"prevWeekClose":0.12,"prevMonthClose":0.13,"prevQuarterClose":0.13,"fiveDayClose":0.099,"twentyDayClose":0.1,"sixtyDayClose":0.115},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NUZ.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528758703","title":"Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528758703","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528758703?lang=en_us&edition=fundamental","pubTime":"2025-04-17 13:25","pubTimestamp":1744867541,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  appointed Kathryn Williams as chief regulatory officer, Jeffrey Brown as chief scientific adviser, and Chris Freitag as chief medical adviser, according to a Thursday Australian bourse filing.Williams has 20 years of experience in regulatory affairs, securing fast track and orphan designations with regulatory bodies, the filing said.Brown also has over 20 years of experience in drug development experience in neurology programs.Freitag is a medical doctor with nearly 30 years of medical and pharmaceutical experience focusing on oncology and rare diseases.The company's shares rose 15% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK7096","NUZ.AU","LENZ","BK4139"],"gpt_icon":0},{"id":"2527922973","title":"Neurizon Therapeutics announces strong safety results in latest study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527922973","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527922973?lang=en_us&edition=fundamental","pubTime":"2025-04-14 12:30","pubTimestamp":1744605000,"startTime":"0","endTime":"0","summary":"Drug candidate NUZ-001 has shown strong safety characteristics in its latest human 3D brain model study, Neurizon Therapeutics  has confirmed this week.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.“This is a very positive result,” Dr Michael Thurn told HotCopper, declaring on the company’s news: “We have been able to show NUZ-001 may have the potential to be a treatment for Alzheimer’s disease and Parkinson’s disease.”“As you know, they are diseases that are becoming more and more important in aging populations so these results really set us up to look at these two indications going forward.”NUZ has been trading 4.7% lower on Monday and is now selling at 10cps.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neurizon-therapeutics-announces-strong-safety-results-in-latest-study-2025-04-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LENZ","NUZ.AU","BK4007","BK4139","BK7096"],"gpt_icon":0},{"id":"2524337278","title":"Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2524337278","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524337278?lang=en_us&edition=fundamental","pubTime":"2025-04-04 14:39","pubTimestamp":1743748793,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said it completed an additional independent study in partnership with a research group at the University of Queensland, to investigate the acute effects of its NUZ-001 drug candidate on the survival of mouse NSC-34 motor neurons following exposure to TDP-43 aggregates and link any changes in viability to enhanced autophagy, according to a Friday Australian bourse filing.Preliminary data suggests that NUZ-001 had a small but significant effect on TDP-43-mediated cell death in the motor neuron cell line. However, despite enhancing survival, acute treatment with NUZ-001 showed no effect on autophagy markers.Autophagy is a critical process for maintaining neural homeostasis, which is recognized as a key therapeutic target in neurodegenerative diseases, the filing said.Researchers treated NSC-34 cells with various concentrations of the drug candidate and compared it to Rapamycin, an autophagy activator over four hours.They analyzed key markers of autophagy activation ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","LENZ","BK4139","BK7096"],"gpt_icon":0},{"id":"2524184320","title":"Neurizon finds positive results for lead drug in 3D brain model study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524184320","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524184320?lang=en_us&edition=fundamental","pubTime":"2025-04-01 08:53","pubTimestamp":1743468780,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics Ltd  has yielded positive results from an independent study – conducted in collaboration with Tessara Therapeutics – which showed its lead drug NUZ-001 produced several positive effects on the brain.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The study analysed the effects of the drug candidate on Tessara’s RealBrain 3D human tissues model – a 3D model of the brain – and found both NUZ-001 and NUZ-001 Sulfone  were safe when applied to a healthy human brain.The two tested drugs also reportedly provided neuroprotective properties against neurotoxic insult  and encouraged the health of brain tissues.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full discl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neurizon-finds-positive-results-for-lead-drug-in-3d-brain-model-study-2025-04-01/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NUZ.AU","BK7096"],"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[]}}